Investor Information Audited


Shares of Lonza Group Ltd are listed on the SIX Swiss Exchange and were included in the Swiss Market Index (SMI) in 2017. Lonza also maintains a secondary listing on the SGX Singapore Exchange. The nominal value of the Lonza Group Ltd share is CHF 1. Lonza's share price closed at the end of 2017 at CHF 263.3, which represents an increase of 49.4% in 2017.

The free float in Lonza Group Ltd registered shares reached 99.7% at year-end, and the average daily trade volume was 314,971 shares in 2017.

Listing and Security Information

Stock Exchange Listing/Trading:

 

  • SIX Swiss Exchange
  • SGX Singapore Exchange

Common Stock Symbols

 

  • Bloomberg LONN SW
  • Reuters LONN.S
  • SIX Financial Information LONN
  • SGX O6Z

Security Number

 

  • Valor 001384101
  • ISIN CH0013841017

Upcoming Financial Events

 

Date and Time Event
   
04 May 2018, 10:00 am CET Annual General Meeting for the Financial Year 2017
Congress Center Basel, Switzerland
04 May 2018 Q1 2018 Qualitative Business Update
08 May 2018 Ex-Dividend Date
09 May 2018 Record-Dividend Date
11 May 2018 Dividend Payment Date
25 July 2018 Half-Year Results 2018
24-26 September 2018 Capital Markets Day (Zurich, Switzerland)
25 October 2018 Q3 2018 Qualitative Business Update
18 April 2019, 10:00 am CET Annual General Meeting for the Financial Year 2018
Congress Center Basel, Switzerland

Shareholdings

 

According to disclosure notifications filed with Lonza, the following shareholders held more than 3% of Lonza's share capital as of 31 December 2017:

Principal Shareholders %
   
BlackRock, Inc., New York, NY (USA) 9.67
Massachusetts Mutual Life Insurance Company, Springfield, MA (USA) 4.06

 

Lonza knows of no other shareholder(s) that owned more than 3% of our share capital as of 31 December 2017. To the best of Lonza’s knowledge, the above-mentioned shareholders are not linked by any shareholders’ agreement or similar arrangement with respect to their shareholdings in Lonza or the exercise of shareholders’ rights. For a full review of the individual disclosure notifications made during 2017, please refer to the SIX Swiss Exchange disclosure platform.

Share Price Development 2017 

 

Share-Price.png

 


Lonza Share Price Development vs. Swiss Leader Index and the Swiss Market Index (Rebased)

 

Lonza-SLI-SMI.png


Dividend Payment History (in CHF/Share)1 

 

Dividend-Payment_Development.png

million CHF 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Lonza Standalone
2017 Lonza Incl. Capsugel
                       
Sales 2,937 2,690 2,680 2,692 3,925 3,584 3,640 3,803 4,132 4,562 5,105
Result from operating activities (EBIT) 441 239 374 261 340 253 423 428 486 728 723
Net capital invested 3,768 3,900 3,688 5,667 5,437 4,958 5,224 4,859 5,026 5,191 11,468
Return on net operating assets (RONOA) in % 13.8 6.7 10.8 6.9 7.5 5.9 10.3 10.8 12.7 19.3 9.7
Headcount 8,462 8,386 8,280 11,001 10,789 9,935 9,809 9,829 10,130 10,979 14,618

Significant News Releases

The most significant news releases during the course of 2017 were the following:

Date News Release
04 January 2017 Lonza Concludes Divestment of Peptides Business and Operations in Braine-l’Alleud, Belgium, to PolyPeptide
25 January 2017 Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech
25 January 2017 Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 
31 January 2017 Lonza Announces the Launch of an Accelerated Bookbuilding
01 February 2017 Lonza Successfully Places 5.0 million New Shares, Raising Gross Proceeds of CHF 865 million
16 February 2017 Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia
27 February 2017 Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility
23 March 2017 Lonza Offers New, Innovative MIT-Free Preservative for In-Can Preservation in Europe
30 March 2017 Lonza Publishes Annual Report 2016 and Invitation to the 2017 Annual General Meeting
25 April 2017 Lonza Starts 2017 with Outstanding First Quarter
25 April 2017 Lonza Announces the Results of the 2017 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
25 April 2017 Lonza Launches Rights Offering
10 May 2017  Lonza Announces the Successful Results of the Rights Offering
16 May 2017 Lonza Invests to Develop Exosomes for Next-Generation Life-Science Applications
30 May 2017 Lonza Acquires Cell and Gene Contract Manufacturer PharmaCell
27 June 2017 Lonza Has Received All Regulatory Approvals to Move Forward with Acquisition of Capsugel
06 July 2017 Lonza Completes Aquisition of Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and Consumer Healthcare Industries
26 July 2017 Lonza Pharma&Biotech Launches Ibex® Solutions – An Innovative New Concept in Biological Manufacturing and Development
26 July 2017 Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth
04 August 2017 Lonza Acquires Micro-Macinazione to Create the Global Leader in Micronization Capacity and Capabilities
22 September 2017 Groundbreaking for the New Large-Scale Biologics Production Facility in Visp (CH)
03 October 2017 Lonza to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Customer Demand
05 October 2017 Lonza Cell & Gene Therapy Facility in Houston, TX, Area to Complete Construction on Schedule in 2017
09 October 2017 Lonza Announces Formation of New Research and Development Collaborative Innovation Center in Israel
26 October 2017 Lonza Reports a Strong Third Quarter and Capsugel Integration on Track
28 November 2017 New Plastics Laboratory Opening at the Lonza Innovation and Technology Center in Alpharetta, GA (USA)
30 November 2017 Lonza, Akouos and MEE Announce Strategic Gene Therapy Licence Agreement on Hearing and Balance Disorders
 

For a comprehensive review of the media releases issued during 2017, refer to www.lonza.com/news